预防医学

订阅

MedSci主页 / 所有栏目 / 预防医学

Clinica Chimica Acta：丙氨酸转氨酶对2型糖尿病发病率的独立影响

2019-09-16 Gladiator MedSci原创

丙氨酸转氨酶2型糖尿病发病率
关注

以往研究表明丙氨酸氨基转移酶<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-fareast-font-family:宋体;mso-bidi-font-family:&quot;Times

以往研究表明丙氨酸氨基转移酶(ALT)可能是糖尿病发病的危险因素之一。本研究目的是明确ALT对突发糖尿病的独立作用，并调查中国普通人群中ALT和突发糖尿病之间的关系是否受年龄和性别的影响。

本研究为回顾性队列研究，包括210,051名中国成年人。主要结果是发展成糖尿病。血清谷丙转氨酶活性按五分位数分层。从“DATADRYAD”网站上获取数据，并利用这些数据进行二次分析。

在3年的中位随访中，210,051名(1.97%)参与者中有4144人患有糖尿病。对潜在的混杂因素校正后，在第五个五分位数（Q5，≥31U/ L）的参与者中发现糖尿病发生率（HR：1.43,95％CI：1.25-1.63）明显高于第一个到第四个五分位数（Q1- 4）ALT。在30至40岁和40至50岁的男性中，与ALT活性较低的患者相比，ALT活性的第五分位数分别增加了2.4倍和1.5倍的糖尿病发病几率。在年龄在30到40岁之间且≥70岁的女性中，ALT活性的第五个五分位点患糖尿病的几率增加了4.9倍和2.2倍。

研究结果表明，ALT活性与中国人群的糖尿病发病呈正相关。此外，在30-40岁的人群中，无论男性还是女性，ALT活性升高的人患糖尿病的风险比同一年龄段ALT活性较低的人要高。

原始出处：

Feng Gao，Xie-lin Huang，Independent effect of alanine transaminase on the incidence of type 2 diabetes mellitus, stratified by age and gender: A secondary analysis based on a large cohort study in China

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823580, encodeId=bc80182358082, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Feb 17 01:08:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849714, encodeId=6f891849e141c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 14 11:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752044, encodeId=47a51e52044ec, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Thu Mar 19 07:08:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395466, encodeId=4053139546686, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 18 08:08:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042704, encodeId=55b41042e04ed, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Sep 16 20:08:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-02-17 lifestar

    #发病率#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1823580, encodeId=bc80182358082, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Feb 17 01:08:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849714, encodeId=6f891849e141c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 14 11:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752044, encodeId=47a51e52044ec, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Thu Mar 19 07:08:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395466, encodeId=4053139546686, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 18 08:08:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042704, encodeId=55b41042e04ed, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Sep 16 20:08:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-03-14 windight

    #CTA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1823580, encodeId=bc80182358082, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Feb 17 01:08:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849714, encodeId=6f891849e141c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 14 11:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752044, encodeId=47a51e52044ec, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Thu Mar 19 07:08:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395466, encodeId=4053139546686, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 18 08:08:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042704, encodeId=55b41042e04ed, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Sep 16 20:08:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-03-19 aliceclz

    #丙氨酸转氨酶#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1823580, encodeId=bc80182358082, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Feb 17 01:08:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849714, encodeId=6f891849e141c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 14 11:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752044, encodeId=47a51e52044ec, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Thu Mar 19 07:08:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395466, encodeId=4053139546686, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 18 08:08:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042704, encodeId=55b41042e04ed, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Sep 16 20:08:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-18 仁医06

    #转氨酶#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1823580, encodeId=bc80182358082, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Feb 17 01:08:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849714, encodeId=6f891849e141c, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Mar 14 11:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752044, encodeId=47a51e52044ec, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Thu Mar 19 07:08:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395466, encodeId=4053139546686, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Sep 18 08:08:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042704, encodeId=55b41042e04ed, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Sep 16 20:08:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

J Gastroen Hepatol：丙氨酸转氨酶是结直肠腺瘤的新生物标志物

研究表明，对于无症状的健康人群，血清丙氨酸转氨酶水平是结直肠腺瘤的生物标志物，特别是男性

J Clin Hepatol：推荐使用统一ALT判断值时应重视的医学检验问题

ALT是临床用以了解患者有无肝细胞损伤的常用实验室检测指标，其临床灵敏度及特异性取决于区分“正常”或“异常”检测结果时所选用的判断值（cut-off point）。过去普遍以“高于检测实验室所推荐的参考区间上限水平”来界定ALT检测结果是否“异常”，该做法对肝脏疾病的诊断灵敏度较高而特异性相对不足，在ALT“升高”情况下需鉴别的疾病范围较广。